EU Approval Set For Three New Orphans And Lilly’s Emgality; Exondys Appeal Fails
Executive Summary
The CHMP has upheld its previous negative opinion on Sarepta’s DMD treatment Exondys, but has given a raft of positive opinions on other novel products, including Lilly’s new migraine prophylactic Emgality, Spark Therapeutics’ gene therapy Luxturna for retinal dystrophy, and Vabomere, The Medicines Co/Rempex Pharmaceuticals’ new antibiotic for severe infections.
You may also be interested in...
Deal Watch: Astellas/Cytokinetics Extend Partnership, Make Progress On SMA Candidate
The two firms hope improvement in the six-minute walk test might be accepted by the US FDA as registrational endpoint for reldesemtiv in spinal muscular atrophy. Blackstone acquires Clarus, while Merck licenses TriNKETs from Dragonfly.
Re-Examination Of Amgen, BMS Filings Highlights Difference Between EU And US Regulators
Unlike in the US, the European Medicines Agency does not usually recommend approval of drugs based on early-phase trials.
Ipsen Sees First Mover Advantage In EU For Cabometyx In Liver Cancer
Ipsen CSO says CHMP recommendation for TKI Cabometyx should give it first mover advantage globally in liver cancer.